GSK Functionally Cures Hepatitis B, Lilly's $3.8B Vaccine Pivot, and Base Editing Holds for 18 Months – This Week in Biotech #102

Key Takeaways

• GSK/Ionis bepirovirsen achieved ~20% functional cure in chronic hepatitis B.
• Lilly spent $3.8 B acquiring three vaccines for shingles, S. aureus, EBV.
• CVS Caremark added Foundayo, restoring Zepbound, expanding Lilly obesity drug coverage.
• Datroway ADC raised overall survival to 23.7 months in triple‑negative breast cancer.
• Verve’s base‑editing cut LDL up to 62% with 18‑month durability.

Pulse Analysis

The Phase 3 results for bepirovirsen mark a watershed moment in hepatitis B therapy. For decades, patients have relied on lifelong nucleoside analogs that suppress viral replication without achieving cure. A 20% functional cure rate after a 24‑week antisense regimen could redefine clinical guidelines, especially in high‑burden regions such as sub‑Saharan Africa and Southeast Asia. Pricing and access strategies will be critical as GSK prepares for an FDA decision later this year, potentially unlocking a multi‑billion‑dollar market.

Eli Lilly’s $3.8 billion vaccine acquisition spree reflects a deliberate pivot from its GLP‑1 blockbuster to a broader prevention platform. By securing a next‑generation shingles candidate, a surgical‑site‑infection vaccine, and a preclinical Epstein‑Barr virus program, Lilly is building a pipeline that leverages its cash flow to acquire delivery technologies and diversify revenue streams. The moves also position the company to compete in high‑margin vaccine markets and mitigate reliance on weight‑loss drugs, signaling to investors a long‑term growth narrative beyond metabolic therapeutics.

Beyond these headline deals, the week highlighted the accelerating maturity of advanced modalities. Daiichi Sankyo’s Datroway ADC becoming first‑line therapy in triple‑negative breast cancer demonstrates that antibody‑drug conjugates can now displace chemotherapy in historically untreatable settings. Meanwhile, Verve’s base‑editing platform showed durable LDL reductions up to 62% lasting 18 months after a single infusion, edging closer to a one‑time gene‑editing solution for hypercholesterolemia. Combined with CVS Caremark’s expanded coverage of Lilly’s obesity drugs, these advances underscore a biotech landscape where curative intent, durable gene‑editing, and strategic diversification are reshaping market dynamics.